Durable response to olaparib combined low-dose cisplatin in advanced hepatocellular carcinoma with FANCA mutation: A case report

To date, there is no actionable gene has been discovered in hepatocellular carcinoma (HCC). Tumor cells with DNA damage response and repair (DDR) gene loss-of-function mutation is sensitivity to poly-ADP-ribose polymerase (PARP) inhibitors and platinum chemotherapy in ovarian, prostate and pancreati...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Yi-Hsuan, Tung, Kai-Che, Chen, San-Chi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524966/
https://www.ncbi.nlm.nih.gov/pubmed/36181052
http://dx.doi.org/10.1097/MD.0000000000030719

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524966/
https://www.ncbi.nlm.nih.gov/pubmed/36181052
http://dx.doi.org/10.1097/MD.0000000000030719

Ejemplares similares